Short answer
Keros Therapeutics, Inc. (KROS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation signals refreshed investor messaging and potentially new company or pipeline information.
Keros Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation signals refreshed investor messaging and potentially new company or pipeline information
- Exhibit 99.1 contains the substantive presentation, available through Keros Therapeutics’ website
- Investors should review the presentation for changes to clinical, regulatory, cash runway, or strategic outlook disclosures
Item EX-99.1 · Exhibit EX-99.1
- November 2026 presentation highlights rinvatercept’s expanding pipeline role across DMD and ALS, increasing potential value beyond a single indication
- Phase 2 DMD basket trial commenced, with initial data expected in first half of 2027
- ALS Phase 2 design discussions with regulators planned for second half of 2026, creating a near-term clinical catalyst
- Elritercept partnership with Takeda provides $200M upfront and over $1.1B potential milestones, with three Phase 3 trials underway
- KER-206 remains nonclinical, with osteoporosis mouse data supporting further development but no human validation yet
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Keros Therapeutics, Inc. 8-K filings
Get the next KROS 8-K as it lands
Follow KROS for push alerts, or ask the research agent what this filing means.